Market Intelligence, Clinical Progress, and High-Purity Reagents for Lymphangiogenesis and Anti-Metastasis Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for FLT4/VEGFR3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FLT4 (VEGFR3) ECD-Fc Fusion Protein, Domain 1-7. HEK293 Expressed (Native Glycosylation), Theoretical MW ~110 kDa, Purity >95% (SDS-PAGE), Endotoxin <1 EU/µg, Sequence Verified. | View FLT4 Products |
| Gene Delivery | FLT4 (VEGFR3) Lentivirus Particles, Full-length ORF (NM_002020), Puromycin selection marker, for stable receptor expression in LECs/CHO. | View FLT4 Products |
| Benchmark Ab | Anti-FLT4 (IMC-3C3 Biosimilar Sequence), Recombinant human IgG1, Positive control for competitive binding and inhibition assays. | View FLT4 Products |
| Validator | FLT4 siRNA Set (3 Unique Targets), For transient knockdown and specificity verification in lymphatic endothelial cells. | View FLT4 Products |
| Related Target A | VEGFC – Primary ligand driving VEGFR3 activation and lymphangiogenesis. | View VEGFC Products |
| Related Target B | VEGFR2 (KDR) – Synergistic angiogenesis receptor for dual-targeting strategies. | View KDR Products |
| Related Target C | VEGFR1 (FLT1) – VEGF-A/B receptor, critical for selectivity counter-screening. | View FLT1 Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Post-translational Modifications | HEK293 Expressed (Native Glycosylation) ensuring correct ECD folding. |
| Cross-species Cyno/Mouse Evaluation | Human, Mouse, and Cyno FLT4 ortholog proteins available (>95% purity, Sequence Verified for epitope conservation). |
| Subfamily Selectivity (VEGFR1/VEGFR2 cross-reactivity) | FLT4/FLT1/KDR ortholog panel (Human/Cyno/Mouse, matched ECD domains) for SPR/BLI selectivity screening. |
| Cell-based Phosphorylation Assays | Full-length FLT4 Lentivirus for stable cell line construction, preserving native kinase conformation and glycosylation. |
| Ligand Competition (VEGF-C/D) | High-affinity FLT4 ECD-Fc suitable as decoy receptor in ELISA/SPR competition assays. |
| Lack of Positive Controls | Clinical Benchmark Antibodies (IMC-3C3 biosimilar) included for precise assay calibration. |
| False Positive Knockdown Validation | FLT4 siRNA Set (3 targets) for specificity checks and target knockdown. |
Live VEGFR3/FLT4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for VEGFR3 (FLT4) therapeutics is intensifying, with major players shifting focus from pan-VEGFR tyrosine kinase inhibitors to highly specific selective FLT4 antagonists, monoclonal antibodies, and bispecifics. As first-generation multi-kinase inhibitors (e.g., sorafenib, sunitinib, lenvatinib) face limitations due to VEGFR2-mediated vascular toxicity, the next wave of R&D is targeting lymphatic-specific pathways for lymphedema and anti-metastasis applications without disrupting blood vascular homeostasis. Selective FLT4 inhibitors (e.g., DCC-3014 from Deciphera) are entering clinical trials for primary lymphedema and solid tumors, while antibody-based strategies (IMC-3C3 legacy, VEGF-C/D traps) aim to block lymphangiogenesis more precisely.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Multi-Kinase Inhibitors (pan-VEGFR) | Eisai, Exelixis | Advanced Solid Tumors | Selectivity Assay (Need high-purity kinase domains for broad profiling) |
| Selective FLT4 TKI | Deciphera, Daiichi Sankyo | Primary/Secondary Lymphedema, Solid Tumors | Kinase Selectivity Panel (FLT4 vs FLT1/KDR), ATP-site mutant proteins |
| Monoclonal Antibodies (Anti-FLT4) | ImClone (legacy), Merrimack, Eli Lilly (historical) | Cancer Metastasis, Lymphangioma | Ligand Blocking Assay & Receptor Internalization Assay (Need HEK293 ECD-Fc and VEGFC) |
| VEGF-C/D Trap | Regeneron, Academic | Lymphedema | Ligand Binding Affinity (SPR/BLI with VEGF-C/D), Endotoxin Control for in vivo |
| Bispecifics / ADC (VEGFR2/3 & FLT4 BiADC) | Emerging Biopharma, Biotech | Refractory Angiogenesis, Lymphatic Metastasis | Heterodimer Validation & Internalization Efficiency + Payload Release Assay |
Domain Architecture & Key Mutations
FLT4 (VEGFR3) is a receptor tyrosine kinase with an extracellular region containing three Ig-like C2-type domains (Ig-like C2-type 1, 2, 3) critical for ligand binding and receptor dimerization. Key mutations associated with hereditary lymphedema and potential drug resistance include:
- Mutation in CHTD7 (UniProt VAR_083806)
- dbSNP:rs34221241 (UniProt VAR_042062)
- Another mutation in CHTD7 (UniProt VAR_083807)
These variants are important for understanding receptor function and for designing allele-specific inhibitors or assessing patient stratification strategies.
Molecular Differentiation & Assay Strategy
To develop best-in-class FLT4-targeted therapeutics, key differentiation factors include:
- Affinity tuning: moderate affinity (Kd ~1-10 nM) or pH-dependent release is advantageous for lymphedema indications to avoid complete blockade of physiological lymphatic drainage. Assay needs: multi-concentration SPR kinetics and pH 6.5-7.4 binding stability testing.
- Subcutaneous (Sub-Q) suitability: high-concentration protein formulation (>50 mg/mL) stability and viscosity testing are critical for chronic lymphedema management. Assay needs: accelerated aggregation studies and viscometry.
- Subfamily selectivity: stringent exclusion of VEGFR2 (KDR) cross-reactivity to avoid cardiovascular toxicity. Assay needs: parallel SPR screening on FLT4/KDR/FLT1 immobilized chips.
- Cross-species reactivity: human/cyno/mouse FLT4 ECD-Fc trio panel for toxicity and efficacy models.
- Internalization efficiency (for ADC): receptor-mediated internalization flow cytometry with fluorescently labeled FLT4 ECD-Fc.
TarMart addresses these needs with rationally designed reagents: full-length ECD (D1-D7) and truncated D1-D3 for ligand binding and dimerization studies; kinase domain wild-type and mutant proteins (e.g., V1041M, G1076A) for resistance profiling; lentivirus for stable cell lines; and validated control antibodies and siRNA.